Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
申请公布号
WO2010056598(A3)
申请公布日期
2010.12.23
申请号
WO2009US63490
申请日期
2009.11.06
申请人
ALLERGAN, INC.;SPADA, LON, T.;GHEBREMESKEL, ALAZAR, N.;ROBINSON, MICHAEL, R.
发明人
SPADA, LON, T.;GHEBREMESKEL, ALAZAR, N.;ROBINSON, MICHAEL, R.